# A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

> **NCT07703475** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 80 (estimated)

## Conditions studied

- COVID -19

## Interventions

- **BIOLOGICAL:** RVX-sCPD9

## Key facts

- **NCT ID:** NCT07703475
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-26
- **Primary completion:** 2027-11-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703475, "A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07703475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*